Shaista Shabbir Jasdanwala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shaista Shabbir Jasdanwala has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed M. Mamdouh
Department of Pharmacy, National University of Singapore, Singapore
35 shared publications - Anthony Letai
Dana-Farber Cancer Institute, Boston, USA
35 shared publications - Binyam Yilma
Tempus AI, Inc, Chicago, IL
35 shared publications - Chuqi Wang
Department of Pharmacy & Pharmaceutical Sciences, National University of Singapore, Singapore 117559, Singapore
35 shared publications - David M. Weinstock
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
35 shared publications - Disha Malani
Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
35 shared publications
Latest Publications
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Table 2 shows sample IDs submitted for RNA-seq.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Table 2 shows sample IDs submitted for RNA-seq.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S12 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 12 shows targeted agents cluster by mechanism of action.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 12 shows targeted agents cluster by mechanism of action.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S4 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Table 4 shows raw baseline BH3 profiling data on matched pre- and post-resistant AML PDX models.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Table 4 shows raw baseline BH3 profiling data on matched pre- and post-resistant AML PDX models.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S10 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 10 shows immunoblotting of FLT-3 signaling pathway in quizartinib-resistant AML PDX models.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 10 shows immunoblotting of FLT-3 signaling pathway in quizartinib-resistant AML PDX models.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S6 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 6 shows drug response data in AML patient samples at diagnosis and relapse.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 6 shows drug response data in AML patient samples at diagnosis and relapse.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Table 2 shows sample IDs submitted for RNA-seq.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Table 2 shows sample IDs submitted for RNA-seq.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 3 shows MDR mechanisms contribute to drug resistance in AML PDX models.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 3 shows MDR mechanisms contribute to drug resistance in AML PDX models.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S7 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 7 shows relapsed or primary refractory AML patients demonstrate reduced ex vivo drug sensitivity compared to diagnosis AML patients.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 7 shows relapsed or primary refractory AML patients demonstrate reduced ex vivo drug sensitivity compared to diagnosis AML patients.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 2 shows RNA-seq signature of drug-resistant AML PDX models.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 2 shows RNA-seq signature of drug-resistant AML PDX models.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 4 shows differential expression of BCL-2 family related genes and proteins in drug-resistant AML PDX models.
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts
Supplemental Figure 4 shows differential expression of BCL-2 family related genes and proteins in drug-resistant AML PDX models.